Smith & Nephew’s Reduce Rating Reaffirmed at AlphaValue (SN)
Smith & Nephew (LON:SN)‘s stock had its “reduce” rating reaffirmed by stock analysts at AlphaValue in a report issued on Thursday, Stock Ratings Network.com reports. They currently have a GBX 712 ($11.40) price objective on the stock. AlphaValue’s price target would suggest a potential downside of 7.89% from the company’s current price.
Shares of Smith & Nephew (LON:SN) traded up 0.71% during mid-day trading on Thursday, hitting GBX 778.50. 405,453 shares of the company’s stock traded hands. Smith & Nephew has a 52-week low of GBX 636.00 and a 52-week high of GBX 805.50. The stock’s 50-day moving average is GBX 778.4 and its 200-day moving average is GBX 761.5. The company’s market cap is £7.045 billion.
SN has been the subject of a number of other recent research reports. Analysts at Numis Securities Ltd reiterated an “add” rating on shares of Smith & Nephew (LON:SN) in a research note to investors on Monday, September 2nd. Separately, analysts at Citigroup Inc. downgraded shares of Smith & Nephew (LON:SN) to a “neutral” rating in a research note to investors on Tuesday, August 13th. Finally, analysts at Societe Generale reiterated a “sell” rating on shares of Smith & Nephew (LON:SN) in a research note to investors on Tuesday, August 6th. They now have a GBX 695 ($11.13) price target on the stock. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 776.94 ($12.44).
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.